Infusystem Holdings, INC

InfuSystem Holdings presents a robust investor update showcasing consistent revenue growth, significant Adjusted EBITDA expansion, and a strategic focus on scaling adjacent therapies and optimizing its platform.

InfuSystem Holdings, Inc. announced its second quarter 2026 financial results, showcasing a 2.6% increase in net revenues to $36.9 million and a 7.6% rise in Adjusted EBITDA to $8.6 million, while reaffirming full-year guidance.

InfuSystem Holdings, Inc. announced it will release its second quarter 2026 financial results on August 4, 2026, and will host an investor conference call.

InfuSystem Holdings, Inc. has approved a $20 million stock repurchase program to run from July 1, 2026, through June 30, 2028, signaling confidence in future growth and financial strength.

InfuSystem Holdings announced the election of Beverly Huss as Chairman of the Board following the 2026 Annual Meeting of Stockholders.

InfuSystem Holdings, Inc. shareholders approved the election of directors and an increase in shares reserved for the 2021 Equity Incentive Plan at the 2026 Annual Meeting.

InfuSystem Holdings, Inc. announced Q2 2026 results showing a 2.6% increase in net revenues driven by strong Patient Services growth, alongside improved gross margins despite higher operating expenses.

InfuSystem reports Q1 2026 net income of $1.0 million, driven by growth in Patient Services despite a decline in Device Solutions revenue.

InfuSystem Holdings, Inc. announced significant increases in net income and gross profit for both the third quarter and first nine months of 2025, driven by Patient Services growth and improved Device Solutions margins.

InfuSystem Holdings, Inc. announced significant revenue and profit increases for the second quarter and first half of 2025, driven by growth in both Patient Services and Device Solutions segments.

InfuSystem Holdings, Inc. reports an increase in net revenues and gross profit for the first quarter of 2025 compared to the same period in 2024, driven by growth in both Patient Services and Device Solutions segments.

InfuSystem Holdings, Inc., a leading provider of infusion pumps and related services, announced a 10.7% increase in net revenues for Q3 2024, driven by growth in both its Patient Services and Device Solutions segments.

InfuSystem Holdings, Inc. reported a significant increase in net revenues and net income for the fiscal year ended December 31, 2025, driven by strong performance in its Patient Services segment and improved gross margins.

InfuSystem Holdings, Inc. reports a 7.2% increase in net revenues and improved profitability for the fiscal year ended December 31, 2024, driven by growth in both Patient Services and Device Solutions segments.

InfuSystem Holdings, Inc. reports a 14.4% increase in net revenue for fiscal year 2023, driven by growth in both Patient Services and Device Solutions segments.

Executive VP and CFO Barry G. Steele acquired over 37,000 shares through the vesting of restricted stock units, signaling continued alignment with shareholder interests.

EVP-Chief HR Officer Jerod Funke acquired 19,753 shares through RSU vestings, bringing his total direct ownership to 29,654 shares.

President and CEO Carrie Lachance acquired over 41,000 shares through the vesting of restricted stock units, bringing her total direct holdings to 266,391 shares.

Executive VP and CIO Addam Chupa acquired over 22,000 shares through the vesting of restricted stock units, bringing his total direct ownership to 61,160 shares.

Director Ronald T. Hundzinski was granted 24,890 stock options in InfuSystem Holdings, Inc. as part of an equity incentive.

Director Scott Shuda was granted 24,890 stock options in InfuSystem Holdings, Inc. as part of a standard equity compensation arrangement.

InfuSystem Holdings, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for May 11, 2026, detailing proposals for director elections, executive compensation, equity plan amendments, and auditor ratification.

InfuSystem Holdings announces record revenue, improved profitability, strategic partnerships, and proposed corporate governance amendments in its 2025 proxy statement.

InfuSystem Holdings has issued a corrected proxy card for its upcoming 2024 Annual Meeting of Stockholders due to a preparation error on the original card.

InfuSystem Holdings reports record revenue for 2023 and outlines proposals for the upcoming annual meeting of stockholders.

Christopher Sansone and his investment entities, Sansone Advisors and Sansone Capital Management, have substantially reduced their beneficial ownership in InfuSystem Holdings, Inc., falling below the 5% reporting threshold.

Minerva Advisors LLC and David P. Cohen have reported a 5.3% beneficial ownership stake in InfuSystem Holdings, Inc. as of December 31, 2025.

Minerva Advisors LLC and affiliated entities, including David P. Cohen, reported a 5.0% beneficial ownership stake in InfuSystem Holdings, Inc. as of October 31, 2025.

AWM Investment Company, Inc. filed an amended Schedule 13G, reporting a 2.8% beneficial ownership in InfuSystem Holdings, Inc. common stock.

AWM Investment Company, Inc. reported a 6.1% beneficial ownership stake in InfuSystem Holdings, Inc., holding 1,272,296 shares of common stock as of June 30, 2025.

The Vanguard Group has filed an amended Schedule 13G, reporting a 4.56% passive ownership stake in InfuSystem Holdings Inc. as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a 1.9% passive beneficial ownership stake in InfuSystem Holdings, Inc. as of June 30, 2025.